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Summary While radiotherapy is proceeding. tumour cells may proliferate. The use of small individual doses
reduces late morbidity. Continuous hy-perfractionated accelerated radiation therapy (CHART). which reduces
overall treatment from 6-7 weeks to 12 days and gives 36 small fractions. has now been tested in multicentre
randomised controlled clinical trials. The trial in non-small-cell lung cancer included 563 patients and showed
improvement in survival: 30% of the CHART patients were alive at 2 years compared with 20% in the control
group (P=0.006). In the 918 head and neck cases. there was only a small. non-significant improvement in the
disease-free interval. In this interim anlavsis there was a trend for those with more advanced disease (T3 and
T4) to show advantage: this will be subject to further analysis when the data are more mature. The earlv
mucosal reactions appeared sooner and were more troublesome with CHART. however they quickly settled: so
far no difference in long-term morbidity has emerged. These results support the hypothesis that tumour cell
repopulation can occur during a conventional course of radiotherapy and be a cause of treatment failure.
Keywords randomised tnrals; non-small-cell lung cancer: head and neck cancer; continuous hyperfractionated
accelerated radiation therapy
Radiotherapy plays an important role either alone or in
combination with surgery and cytotoxic chemotherapy in the
management of many primary malignant tumours. When
employed as the single modality to achieve local cure. the
commonest schedule currently employed worldwide requires
daily treatment from Monday to Friday over a period of 6 to
7 weeks. Using an individual dose of 2 Gy. total tumour
doses between 60 Gy and 70 Gy are achieved. Developments
in radio and tumour biology have now led to a re-
examination of this established conventional scheduling of
radiotherapy.
Giving radiotherapy in many small doses has been shown
to reduce the long-term effects in a number of normal tissues
with little reduction in effect upon most tumours (Withers.
1992; Fowler. 1989). Treating in this way. higher total doses
are tolerated by the normal tissues and greater tumour
control can be achieved (Horiot et al., 1992).
Increased knowledge of the cell kinetics of human tumours
has been gained by the administration of bromodeoxyuridine
followed by a tumour biopsy after 4 to 8 h and analysis using
flow cytometry (Begg et al.. 1985). When untreated cancers
are observed, they usually take between 25 and 100 days to
double their volume (Charbit et al.. 1971). In contrast. cell
kinetic studies now show mean potential cell doubling times
ranging from 4 to 7 days for tumours in the head and neck.
lung, uterine cervxVX and digestive tract (Dische and Saunders.
1995). An extension of the technique has allowed identifica-
tion of the cells preparing for division in histological material
and has shown that in most squamous cancers there are areas
where there is a potential for the number to double in less
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than 2 days (Bennett et al., 1992). High cell loss factors owing
to maturation and degeneration largely account for the
difference between the volume doubling times and potential
cell doubling times ofthese tumours (Denekamp, 1982). When.
after cytotoxic chemotherapy or radiotherapy, large numbers
oftumour cells are destroyed. these cell loss factors may greatlN
diminish and a repopulation of the tumour occur during the
intervals between individual treatments (Tubiana. 1988).
In order to minimise repopulation. attempts have been
made to reduce the overall duration of the course of
radiotherapy. However. when treatment is 'accelerated'
reactions in the normal tissues are more severe. especially if
the normal dose increment of 2 Gy is employed. thus making
it difficult to achieve adequate total doses (Peracchi and Salti.
1981; Olmi et al.. 1990). Most approaches have incorporated
individual doses lower than 2 Gy and have attempted to
reduce overall time by only 1 or 2 weeks (Dische and
Saunders, 1995).
Among the recently introduced regimens. continuous
hyperfractionated accelerated radiation therapy (CHART).
first used at Mount Vernon in Januar- 1985. was unique in
that it reduced the overall duration of treatment to the
shortest period attempted - 12 days (Sanders et al.. 1991). A
small dose of 1.5 Gy was given three times per day on every
day. including Saturday and Sunday. Immediate tolerance to
the regimen was better than anticipated and there was
evidence that the long-term effects in normal tissues were
reduced. When, in head and neck cancer. a historical
comparison was made with previously treated patients.
improved local tumour control was observed. In locally
advanced non-small-cell lung cancer (NSCLC) there was, in a
similar analysis. improved local tumour control and survival
(Saunders et al.. 1991).
Following a review by a committee appointed by the
Cancer Research Campaign. the Medical Research Council
and the Department of Health, randomised controlled clinical
trials on a multicentre basis were planned in 1989 in head and
neck cancer and in NSCLC. The objective was to determine
if CHART could yield greater tumour control and or reduce
morbidity compared with conventional radiotherapy. The
hypothesis that cellular repopulation is important as a cause
of failure in radiotherapy would be tested.Randomised trias f CART vs c n- iona d ai§hetqay A Saunders et ai
Method
Trial design
The CHART regimen was compared with conventional
schedules representative of international practice. A 3:2
randomisation in favour of CHART allowed maximum
accrual of patients and facilitated the organisation of giving
CHART in each centre. Observation was made of local
tumour control, metastasis, survival and morbidity.
All patients overthe age of18 years considered suitable for a
radical course of external beam radiotherapy as the definitive
treatment were considered for inclusion. In the head and neck
cancer study, those with early tumours (Ti NO) of the oral
cavity, oropharynx, hypopharynx andlarynx wereexcluded but
all stages of nasal sinus and nasopharyngeal carcinoma were
included: histological proof of squamous carcinoma was
essential. All cases of NSCLC confined to the thorax and
proven by histology or unequivocal cytology were eligible for
inclusion. In both studies any suspicion of distant metastasis
excluded the patient and the WHO performance status was
required to be 0 or 1. Co-existing disease prejudicing survival
excluded thepatient, as did anypossibility thatfollow-up study
might not be completed.
Pretreatment investigations
In the patients with head and neck cancer, mandatory
investigations were limited to a chest radiograph, blood count
andhistologicalexamination ofthetumour. Examinationunder
anaesthesia was required whenever necessary for assessment;
other radiological investigations, including magnetic resonance
and computed tomography (CIT) imaging, were performed as
indicatedfortheindividualpatient. InthepatientswithNSCLC,
mandatoryinvestigationsincludedachestradiograph,broncho-
scopy, CT scan ofthe chest, which was extended to include the
upperabdomen, andhistology or brush cytology. The presence
ofdistant metastasis was assessed by serum biochemistry and
either ultrasound, CT or isotope scan of the liver. Other
investigations were only carried out ifclinically indicated.
The planning ofradiotherapy
The planning process was identical for all patients regardless of
randomisation. Radiation doses were prescribed to the
intersection point as defined by international recommenda-
tions (ICRU, 1978). During the main part of the course of
treatment, the volume irradiated included the primary tumour,
Table I Contributing centres and entry
Head and Non-small-
Centre neck cell lung Total
Bristol Oncology Centre, Bristol 77 24 101
Velindre Hospital, Cardiff 25 34 59
Clatterbridge Hospital, 51 122 173
Merseyside
Carl Gustav Carus, Dresden 38 39 77
Beatson Oncology Centre, 176 71 247
Glasgow
County Hospital Rykov, - 3 3
Jonkoping
Cookridge Hospital, Leeds 105 33 138
Mount Vernon Hospital, 169 70 239
Northwood
Nottingham General HospitaL 47 50 97
Nottingham
St Mary's Hospital, Portsmouth 32 11 43
Royal Marsden Hospital, 70 40 110
London and Surrey
Weston Park Hospital, Sheffield 128 52 180
University Hospital, Umea - 14 14
918 563 1481
any involved lymph nodes and the area oflymphatic drainage.
The final small volume included only the primary tumour and
known nodal involvement together with a margin. In the
patients with head and neck cancer, guidelines were given as to
the lymphatic drainage areas to be included and this varied
according to the site of the primary tumour and the known
spread ofdisease. The variation in radiation dose through the
tumour volume in the central plane, from maximum to
iinimum, was normally limited to 10% of the prescribed
dose.
Conventional radiotherapy
All patients received a daily treatment dose of2 Gy which was
given 5 days per week. In both trials, the main or large volume
received 44 Gy in 22 fractions. The small volume in the head
and neck patients then received 22 Gy in 11 fractions while in
thepatientswithlung cancer 16 Gy wasgivenineightfractions.
Total doses in the two trials were therefore 66 Gy given over45
days and 60 Gy given over 42 days. These different doses were
set recognising the larger areas normally treated in the chest
and the greater sensitivity of some intrathoracic tissues. Both
doses accorded with existing protocols for curative radio-
therapy employed in a majority ofthe contributing centres.
CHART
A dose of 1.5 Gy was given three times on each of 12
consecutive days including the weekend. An interval ofat least
6 h was required between treatments. The large volume dose
was 37.5 Gy in 25 fractions, followed by 16.5 Gy in 11
fractions to the small volume, giving a total of 54 Gy. Based
upon the experience of the pilot study, identical doses were
given in both head and neck and lung cancer trials.
Spinal cord dose
In view ofthe known sensitivity ofthe spinal cord to radiation
injury, particularly with accelerated regimens of treatment,
spinalcorddoses were restricted forboth arms(Van DerKogel,
1989). For conventional radiotherapy, it was required that this
dose should not normally exceed 44 Gy and never exceed
48 Gy, whereas with CHART the corresponding doses were
40 Gy and 44 Gy.
Quality assurance
A quality assurance team comprising a physicist, radiographer
and bioengineer, drawn from the staffat the Cancer Treatment
Centre at Mount Vernon, visited all centres to monitor the
delivery of radiotherapy. Included among the checks was the
use of 'phantom' patients so that the closest observation of
delivery could be made. A data manager and radiotherapist
also took part in a quality assurance survey ofthe data at each
UK centre, when completed proformas were compared with
records often randomly selected patients.
Ethical considerations
Approval for the study by the local ethics committee was
mandatory before patients could be randomised. The nature of
the study was explained to the patients and their written
consent obtained.
Randomisation, design and analysis
In the trial in head and neck cancer, stratification was by
centre, age, tumour site and nodal status. Assuming a 2 year
local control rate of 45% in the conventional arm, it was
calculated that an entry of 500 patients (230 events) was
needed to detect an improvement of 15%, i.e. from 45% to
60% with a power approaching 90% at the 5% level of
significance.
In NSCLC, stratification was by centre, nodal status andWHO performance status. Assuming a 2 year survival rate
of 15% in the conventional arm 600 patients (475 events)
were needed to detect an improvement of 10% in survival,
i.e. from 15% to 25% with a power approaching 90% and a
5% level of significance.
Randomisation was performed by the method ofminimisa-
tion by a telephone call to MRC Cancer Trials Office.
Survival and disease-free interval curves were formed by
the Kaplan-Meier method and compared using the Mantel-
Cox version of the log-rank test. To assess whether CHART
was more or less effective in well-defined subgroups, a X2 test
for heterogeneity or, when appropriate, trend was performed.
All analyses were performed on an intention-to-treat basis, all
tests are from the x2 distribution with one degree of freedom
and all P-values were two-sided unless otherwise specified.
The statistical methods used were implemented using BMDP
and SAS (Parmar and Machin, 1995).
Health technology assessment
The Centre for Health Economics of the University of York
was commissioned to perform a socioeconomic comparison
of treatments in parallel to the clinical study. The resources
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measured included those of radiotherapy centre, the hospital
and the community as well as the cost of travel. The quality
of life was assessed before, during and after treatment using
the Rotterdam Symptom Check List and the Hospital
Anxiety and Depression Scale. A separate report of this
component of the trials is in preparation.
Support for the trial
The Medical Research Council provided funds for data
collection and for data management at the MRC Cancer
Trials Office at Cambridge. The Health Departments made
available funds to cover the additional service costs of the
trial in order that participation by UK centres should not be
prejudiced.
Data monitoring committee
An independent Data Monitoring Committtee was estab-
lished to review, in confidence, the progress of the trial at
approximately annual intervals. At no time did the Data
Monitoring Committee recommend that accrual to the trials
cease before the final closure on 1 April 1995. A separate
Table H Basic data
Head and neck Non-small-cell lung cancer
CHART Conventional CHART Conventional
Age (years)
31-40
41-50
51-60
61 -70
71-80
81>.
Sex
Male
Female
WHO performance status
0
2
Unknown
Site
Oropharynx
Hypopharnyx
Larnyx
Oral cavity
Nasal sinus
Nasopharnyx
Stage
TIS
TI
T2
T3
T4
Unknown
NO
NI
N2
N3
Unknown
Histology (or cytology for lung)
Squamous cell
Well differentiated
Moderately differentiated
Poorly differentiated
Not specified
Large-cell carcinoma
Adenocarcinoma
NSCLC
Other carcinoma
Unconfied
16
73
136
192
119
16
3%
13%
25%
35%
22%
3%
3
49
91
138
73
12
1%
13%
25%
38%
20%
3%
417 76% 270 74%
135 24% 96 26%
361
191
0
0
141
53
254
79
7
18
0
14
234
179
117
8
360
85
69
30
8
109
221
115
95
65% 258
35% 107
0
1
26%
10%
46%
14%
1%
3%
3%
43%
33%
22%
66%
16%
13%
6%
98
34
170
47
6
11
1
13
174
111
63
4
234
52
53
23
4
20% 72
41% 142
21% 80
18% 68
12 4
71% 135
29% 202
1
0
27%
9%
46%
13%
2%
3%
4%
48%
31%
17%
65%
14%
15%
6%
20% 39
39% 70
22% 83
19% 73
22
23
18
1
9
552 356 338
2
22
81
144
85
4
1%
7%
24%
43%
25%
13
56
98
54
3
0%
6%
25%
44%
24%
267 79%
71 21%
166 74%
59 26%
40% 95
60% 130
0% 0
0
42%
58%
0%
29
145
82
71
11
157
42
114
9
16
9%
44%
25%
22%
49%
13%
36%
3%
12%
21%
25%
22%
7%
7%
5%
7%
47%
25%
20%
49%
14%
34%
3%
11%
20%
28%
24%
6%
7%
3%
1%
15
104
54
45
7
106
30
75
6
8
25
43
62
52
14
15
7
2
5
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report from the Data Monitoring Committee is in prepara-
tion.
Results
During 5 years of accrual, 918 patients with head and neck
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6 7 8 cancer and 563 with NSCLC were entered by 13 centres ( able
I). The peak of entry to the head and neck study was in the
secndr venr ofthe trinl hut subhseoueuntlv an averaye of 12 canse
were included each month. Entry to the lung study was at a
lower level but maintained at around ten cases per month
during the whole period of accrual. A review of the patient
characteristics (Table II) shows that apart from a minor trend
towards inclusion of patients with more advanced T stage
disease in the CHART head and neck groun- there was eoual ~~ ~~ ~ W1W&WX 7s
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6 7 8 randomisation ofthe known factors which could influence the
outcome of treatment ofthe two tumours.
Two patients entered to the head and neck trial proved
ineligible; the stage in one was too early and the other was
of unsuitable histology. Both were randomised to the
conventional arm. Four patients in the lung trial were also
ineligible because one had a performance grade of 2 and 3
-| l showed unsuitable histology. They were randomised equally
6 7 8 to the two arms. All six have been included in this interim analysis.
There was a high degree of conformity to protocol,
including the delivery of the planned radiotherapy. The size
of the treatment fields and the homogeneity of radiation
dose through the volumes irradiated were similar in both
arms of both trials. Deviations from the protocol were
slightly greater in the conventional arms but the differences
L LJ between the treatment groups were small and to be expected
6 7 8 when a course of radiotherapy given over a short period of
12 days is compared with one extending over 42 or 45 days.
The quality assurance team found a high level of precision
in treatment delivery in all the centres taking part and in
repeat visits the small variance in the values obtained was
reduced even further. Detailed results will be reported
elsewhere. No errors of any importance were encountered
in the comparison of the data with the case notes.
6 7 8
Early reactions to radiotherapy
The reactions within the mucosae of the oral cavity and
pharynx appeared sooner and were more severe in the
- -=- CHART-treated patients. They lasted, however, for a shorter
period and subsided as completely as did those in the
conventionally treated group (Figure la). In contrast, the
l LJ reactions in the skin, although they appeared sooner, were
6 7 8 less marked in the CHART-treated cases and quickly settled
(Figure lb). Intermediate morbidity was assessed at 8 weeks
and 3 months, by which time early reactions had largely
subsided in both treatment groups.
In the lung study, moderate or severe dysphagia affected
49% of the CHART cases compared with only 19% of those
conventionally treated. However, dysphagia settled quickly in
the CHART-treated patients and in both arms there was little
persistence with this early reaction beyond 6 weeks (Figure lc). 7 8
7 8
Time (weeks)
Figure 1 (a) The percentage of patients showing erythema and
dry desquamation of skin when treated by CHART ( ) and by
conventional radiotherapy (- - -) for head and neck cancer. The
observations were made upon 530 patients treated with CHART
and 357 treated conventionally. The fewest number of records
were made in week 7 when 433 and 298 patients were observed.
(b) The percentage of patients showing membranous reactions in
the oral and oropharyngeal mucosa and reporting moderate or
severe difficulty with swallowing, pain on swallowing and
requiring analgesia when treated by CHART ( ) and by
conventional radiotherapy (- - -) for head and neck cancer.
Numbers of patients observed were as above. (c) The percentage
of patients reporting dysphagia and requiring analgesia when
treated by CHART ( ) and by conventional radiotherapy
(--- -) for NSCLC. The observations were made upon 338 patients
treated with CHART and 225 treated conventionally. The fewest
number of records were made in week 6 when 315 and 199
patients were observed.
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During the first year, there were five cases of transient
myelitis (l'Hermittes syndrome) in the head and neck study;
three were in the CHART arm and two in conventionally
treated cases. There were six cases in the lung study but all
had been treated by CHART.
Late reactions to radiotherapy
In later follow-up, episodes ofchondritis, cartilage necrosis or
osteonecrosis were reported in 3% ofthe cases in both arms of
the head and neck trial. In the majority, spontaneous healing
took place. Analyses of late radiation change observed in the
normal tissues in the head and neck region have so far shown
no difference between the two arms. In the patients treated for
NSCLC, the incidence of radiation fibrosis in the lung and of
dysphagia considered caused byradiotherapy has been low and
similar in both arms of the study. No case of established
radiation myelitis has presented in either study.
Tumour control
In the head and neck trial, disease-free interval was slightly
better for CHART with a margin of 3% between the two
curves in the life table (Figure 2a). This difference was not
statistically significant (P=0.33, x2=O.95), with a hazard
ratio of 0.92 (95% confidence interval 0.76- 1.11). There was
no evidence that there was a difference in the size of
treatment effect in different subgroups defined by primary
site, tumour grade, nodal status, age, performance status or
sex. However, there was evidence that CHART was more
effective than conventional radiotherapy with increasing
tumour stage (x2 for trend=3.40, P=0.065) (Figure 2b-d).
In the lung trial, complete tumour regression was
observed in 34% of CHART patients and 29% of the
conventionally treated patients. There was a trend for the
improved tumour control to be maintained with CHART
but this did not reach statistical significance (P=0.15,
x2=2.04).
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Table m Principal cause of death
Head and neck Non-small-cell lung cancer
Principal cause of death CHART Conventional CHART Conventional
Primary tumour 81 (36%) 62 (45%) 136 (62%) 96 (60%)
Lymph node metastases 17 (8%) 5 (4%) 49 (22%) 37 (23%)
Post-radiation damage I 0 3 (1%) 3 (2%)
Distant metastases 39 (17%) 19 (14%) 29 (13%) 21 (13%)
Coincidental disease 72 (32%) 43 (31%) 0 0
Complications of other treatment 11 (5%) 7 (5%) 3 (1%) 2 (1%)
Unknown 2 (1%) 3 (2%) 0 0
Total 223 139 220 159
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Survival
Among the head and neck patients, 362 deaths have occurred
so far, whereas 379 of those with lung carcinoma have died
(Table III). Death due to the primary tumour was the main
cause of death in both trials but 32% of the deaths in the
head and neck trial were due to coincidental disease and 5%
to complications of other treatment given subsequently. In
the lung study, only 13% of deaths were accounted to
coincidental disease and 1% due to complications of other
treatment.
In the head and neck study, the overall survival showed no
difference between the two groups, but in the NSCLC trial
there was improved survival for the CHART-treated patients
(Figure 3a) with a hazard ratio of 0.75 (confidence interval
0.61-0.93, P=0.006, X2=7.63). At 2 years, 30% of the
CHART-treated patients were alive and 20% ofthose treated
conventionally. There was a trend towards CHART being
more effective with more advanced tumour stage but this did
not reach statistical significance (P=0.29, X2 = 1.13) (Figure
3b-d).
Disui
When the CHART regimen was introduced, it was suggested
that early reactions in both the skin and the mucosa would
be more severe than with conventional treatment. Previously
reported clinical trials ofaccelerated radiotherapy which were
completed in 2 weeks using a conventional 2 Gy dose fraction
in head and neck cancer resulted in mucosal reactions of
great severity which in some cases did not heal and led on to
necrosis (Peracchia and Salti, 1981; Olmi et al., 1990). The
use of a small dose per fraction (1.5 Gy) appeared to
ameliorate the acute mucosal reactions which, although they
appeared earlier and were more troublesome than with
conventional treatment, settled sooner, with no more cases
of persistence than with conventional treatment.
Of special interest was the diminished reaction in skin.
Completion of all radiotherapy before significant reaction
was visible in the skin may have increased tolerance because
when compensatory proliferation in the normal skin occurred
it could proceed without inhibition by further irradiation. A
similar finding has now been reported in the skin of pigs
(Hopewell and Van Den Aardweg, 1991). The use of
CHART in those patients where the full thickness of skin
must be irradiated has given a well-tolerated reaction unlike
that normally observed with conventional radiotherapy
(Dische, 1992).
Transient myelitis after radiotherapy is not associated with
any long-term problem (Jones, 1964). It appeared to be
associated with CHART in the lung trial but the distribution
in the head and neck trial was exactly according to
randomisation.
In both trials, the late changes owing to radiation so far
observed have been similar in both arms. Further follow-up
will show whether the diminished late change associated with
CHART and demonstrated in the pilot study will be observed
in the randomised trials (Saunders et al., 1991).
For this interim report the disease-free survival ofthe head
and neck patients is reported. As distant metastasis was
usually associated with failure in the primary tumour and/or
nodes, this closely parallels disease-free probability within the
irradiated volume. The definitive report to be produced when
the data mature will fully detail the outcome in these
patients.
In the conventionally treated arms of the trials, the
predicted tumour-free survival of 45% for the head and
.5
U)
100
80
60
40
20
0
a
I
0
Numbers at risk
Chart 338
Conventional 225
6 12 18 24
Time (months)
160
93
58
27
30 36
b
Time (months)
Numbers at risk
24 Chart 174
7 Conventional 119
-
C/)
c
n
)o
0 6
Numbers at risk
Chart 82
Conventional 54
.5
U)
80
60
40
20
12 18 24 30 36
Time (months)
39
21
16
6
Numbers at risk
4 Chart 71
2 Conventional 45
d
I
|
It-,~~~~~~~~~~~~~~~~
I l I l I I
u0 6 12 18 24
Time (months)
34
16
14
4
Fugwe 3 Non-small-cell lung cancer. Life tables showing the overall survival of patients treated by CHART ( ) and by
conventional radiotherapy (-
- -). (a) All cases. (b) TI and T2. (c) T3. (d) T4.
6
86
55
28
17
10
4
30 36
10
2
..
I.t
0-
. _
1C 100
4Rmsdoni sdmWS d CHART .s co_ uind ra -xlhrapy
I SaUnders et i
1461
neck cases was exactly reproduced in the randomised trial
while in patients with lung carcinoma there was 20% survival
at 2 years compared with a predicted 15%. Disease-free
interval was considered the most sensitive indicator of the
treatment effect in the head and neck cases; it was almost
identical to recurrence rate within the treatment volume;
distant metastasis without local failure was rare. In NSCLC,
the measurement of local response and detection of
recurrence is more difficult to achieve and thus survival was
considered to be the principal end point. Where there has
been intensive study of primary tumour control in NSCLC,
the complete clearance of tumour has been a strong predictor
of survival (Saunders, 1991).
Patients presenting with head and neck cancer and those
with lung cancer commonly have a history of heavy cigarette
smoking and often of high alcohol consumption. Their
survival is therefore prejudiced not only by the presence of
the tumour for which they are being treated but by the
other conditions associated with their lifestyle. The difference
between the trials in the incidence of death due to
coincidental disease can, in part, be related to the longer
survival of the head and neck patients. The greater
possibility of a salvage procedure for recurrence of
metastases-surgery and cytotoxic chemotherapy-accounts
for the 5% incidence of death due to complications of other
treatment of which there were only 1% in the patients with
lung cancer. Deaths considered due to radiotherapy were
rare in both studies.
The trend for improved local tumour control by CHART
compared with conventional treatment with increasing stage
ofdisease occurred also in the pilot study ofCHART in head
and neck cancer (Saunders et al., 1991). The data on which
this interim report is based were obtained on the same day as
case accrual ceased. With further follow-up considerably
more data will be available for subgroup analysis and to test
the view that patients with advanced stage disease obtained
greater benefit with CHART than those with tumours at
earlier stages.
Tumour control in the earlier stages of head and neck
cancer appeared in both arms of the trial. The choice of
CHART for such patients may still be appropriate if a
reduction in late morbidity is demonstrated and if the
observation that surgery after CHART is easier than after
conventional radiotherapy is confirmed in further follow-up.
It was apparent that, although patients were prepared to be
randomised, a large majority found the completion of all
treatments in a 12 day period preferable to daily attendance
over a period of 6 to 7 weeks even though a stay in a hostel
or ward might be required for the three times a day
treatment. (M Leslie, S Dische and MI Saunders, in
preparation). The patients' choice may therefore influence
the selection of treatment schedule towards CHART.
Sophistication in the delivery of radiotherapy now
available using conformal techniques may allow higher
doses to be achieved using CHART at the site of gross
tumour without increase in morbidity. Further, it may be
possible to combine the accelerated treatment with cytotoxic
chemotherapy. Using these approaches, additional margins of
benefit may be achieved. The CHART regimen may also be
applied with advantage to tumours at other sites.
To achieve completion of CHART in 12 days, the total
dose was reduced to 54 Gy. It was originally anticipated that
the benefit of overcoming tumour cell repopulation would
more than compensate for a reduction in the total radiation
dose of 12 Gy to the head and neck tumours and 6 Gy to the
lung carcinomas. The results of the randomised controlled
clinical trials confirm this view and show that the
disadvantage of a small reduction in total dose can be
outweighed by the benefit of reduced overall time. The
differences in result seen between the two trials may be
related to the 18% reduction in total dose required to give
CHART to the head and neck cases and the 9% for those
with lung cancer.
The potential for tumour cells to proliferate rapidly may
occur at other sites and have a wide importance in oncology.
After surgical resection of tumour, any residual cells may
proliferate rapidly in the well-vascularised post-surgical bed.
Between cycles of cytotoxic chemotherapy residual tumour
cells may be expected to divide rapidly. The shortening of
overall time associated with dose intensification in cytotoxic
chemotherapy should, in itself, give advantage. The evidence
gained in patients treated by radiotherapy showing the ability
of tumour cells to proliferate rapidly suggests that when the
plan of management is for a combination of treatment
modalities - surgery, radiotherapy and cytotoxic chemother-
apy - rest intervals between each should be kept as short as
possible. Once cancer treatment commences, the greatest
success may follow the completion of all its phases in the
shortest overall period of time.
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